Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

​

Tango Therapeutics and Erasca have begun enrolment for a Phase I/II trial assessing the combination of oral therapies ERAS-0015 and vopimetostat in patients with lung and pancreatic cancers.

The post Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.